RHD*25 - RHD*DNB
(ISBT table: RHD partial D v5.0)
This entry is an RHD allele.
DNB, RHD(G355S), RHD*1063A, RHD*1063A (DNB, RHD*25), RHD*1063G>A,
Molecular data
Phenotype
Main D phenotype: D positive (last update: Dec. 28, 2020)Reports by D phenotype
Other RH phenotypes: RH:-3, -4, -30,
Serology with monoclonal anti-D
Antigen Density (Ag/RBC)
More phenotype data
Haplotype
Main CcEe phenotype association: Ce (last update: Jan. 8, 2021)ce | Ce | cE | CE | |
---|---|---|---|---|
ce | 0 | 15 | 0 | 0 |
Ce | 1 | 0 | 0 | |
cE | 0 | 0 | ||
CE | 0 |
Reports by CcEe phenotype
Reports by allele association
Alloimmunization
Antibodies in carriers
Antibody specificity: D (RH1)
Summary: allo-anti-D (last update: Dec. 28, 2020)Detailed information
-
Wagner FF et al. Blood (2002)
- Ab specificity: D (RH1)
- Number (auto- or allo-):
- Number listed as allo-: 5
- Number listed as auto-:
- Number of carriers of the allele assessed:
- DAT: ND
- Autologuous control: ND
- Elution: ND
- Autoadsorption: ND
- Titer: 4 to 128
- Was anti-LW excluded?: yes
- Other antibodies detected: ND
- Cross matches (with Ab and RBCs from different partial types): ND
- Transfusion history: at least 3 had been transfused (the male and at least 2 of the females)
- Pregnancy history:
- Anti-D Ig history: ND, probably none
- Context: ND
- Hemolytic consequences: no clinical data for transfusion reactions or hemolytic disease of the fetus and the newborn
- Comment: anti-D was still detectable 8 years following the last possible immunization event
von Zabern I et al. Transfusion (2013)
Wagner FF et al. Transfus Med Hemother (2014) (RIR n°2, 3, 7, 8, 41)
-
Lukacevic Krstic J et al. Transfus Med Hemother (2016)
- Ab specificity: D (RH1)
- Number (auto- or allo-): 1
- Number listed as allo-:
- Number listed as auto-:
- Number of carriers of the allele assessed:
- DAT:
- Autologuous control:
- Elution:
- Autoadsorption:
- Titer:
- Was anti-LW excluded?:
- Other antibodies detected:
- Cross matches (with Ab and RBCs from different partial types):
- Transfusion history: potentially exposed through transfusion
- Pregnancy history:
- Anti-D Ig history:
- Context:
- Hemolytic consequences: HDN: 2 babies with positive DAT
- Comment: see publication for more detail
-
Wagner FF et al. Blood (2002)
- Ab specificity: D (RH1)
- Number (auto- or allo-):
- Number listed as allo-: 1
- Number listed as auto-:
- Number of carriers of the allele assessed:
- DAT: ND
- Autologuous control: ND
- Elution: ND
- Autoadsorption: ND
- Titer: ND
- Was anti-LW excluded?: yes
- Other antibodies detected: ND
- Cross matches (with Ab and RBCs from different partial types): ND
- Transfusion history: ND
- Pregnancy history:
- Anti-D Ig history: ND, probably none
- Context: ND
- Hemolytic consequences: ND
- Comment:
von Zabern I et al. Transfusion (2013)
Wagner FF et al. Transfus Med Hemother (2014) (RIR n°49)
-
von Zabern I et al. Transfusion (2013)
- Ab specificity: D (RH1)
- Number (auto- or allo-):
- Number listed as allo-: 3
- Number listed as auto-:
- Number of carriers of the allele assessed:
- DAT: ND
- Autologuous control: ND
- Elution: ND
- Autoadsorption: ND
- Titer: ND
- Was anti-LW excluded?: yes
- Other antibodies detected: ND
- Cross matches (with Ab and RBCs from different partial types): ND
- Transfusion history: ND
- Pregnancy history:
- Anti-D Ig history: ND, probably none
- Context: ND
- Hemolytic consequences: ND
- Comment:
Wagner FF et al. Transfus Med Hemother (2014) (RIR n°89, 90, 104)
-
St-Louis M et al. Immunohematology (2011)
- Ab specificity: D (RH1)
- Number (auto- or allo-):
- Number listed as allo-: 2
- Number listed as auto-:
- Number of carriers of the allele assessed: 2
- DAT: negative
- Autologuous control:
- Elution:
- Autoadsorption: not auto adsorbable
- Titer:
- Was anti-LW excluded?:
- Other antibodies detected:
- Cross matches (with Ab and RBCs from different partial types):
- Transfusion history:
- Pregnancy history:
- Anti-D Ig history:
- Context:
- Hemolytic consequences:
- Comment: among 2 RHef00082 individuals: 2 had allo-anti-D, 1 exposed through transfusion or pregnancy, 1 through transfusion
-
Guzijan G et al. Transfus Med Hemother (2019)
- Ab specificity: D (RH1)
- Number (auto- or allo-): 1
- Number listed as allo-:
- Number listed as auto-:
- Number of carriers of the allele assessed: 2
- DAT: ND
- Autologuous control: ND
- Elution: ND
- Autoadsorption: ND
- Titer: ND
- Was anti-LW excluded?: ND
- Other antibodies detected: ND
- Cross matches (with Ab and RBCs from different partial types): ND
- Transfusion history: ND
- Pregnancy history:
- Anti-D Ig history: ND
- Context: pregnant woman
- Hemolytic consequences: ND
- Comment:
-
Quantock KM et al. Transfusion (2017)
- Ab specificity: D (RH1)
- Number (auto- or allo-):
- Number listed as allo-: 1
- Number listed as auto-:
- Number of carriers of the allele assessed:
- DAT: weakly positive (C3d only)
- Autologuous control: ND
- Elution: ND
- Autoadsorption: ND
- Titer: 2 at 28 weeks gestation, 256 at 33 weeks
- Was anti-LW excluded?: ND
- Other antibodies detected: anti-E (titer 1, steady during pregnancy)
- Cross matches (with Ab and RBCs from different partial types): ND
- Transfusion history: potentially exposed through transfusion
- Pregnancy history:
- Anti-D Ig history: ND, probably none
- Context:
- Hemolytic consequences: HDN requiring phototherapy and intraveinous immunoglobulin
- Comment:
-
Daniels G et al. Br J Haematol (2013)
(review; Table I)
- Ab specificity: D (RH1)
- Number (auto- or allo-):
- Number listed as allo-: no new case detailed (listed as allo-anti-D)
- Number listed as auto-: NA
- Number of carriers of the allele assessed: NA
- DAT: NA
- Autologuous control: NA
- Elution: NA
- Autoadsorption: NA
- Titer: NA
- Was anti-LW excluded?: NA
- Other antibodies detected: NA
- Cross matches (with Ab and RBCs from different partial types): NA
- Transfusion history: NA
- Pregnancy history:
- Anti-D Ig history: NA
- Context: NA
- Hemolytic consequences: NA
- Comment: list of D variants associated with alloanti-D formation
Antibodies in D negative recipients
Alloimmunization in recipients: expected to be possible, see phenotype data
Reports
Summary: several descriptions, in Central Europeans (last update: Dec. 28, 2020)Detailed reports
- 2 samples RIR n°7, n°8 in the Austrian population
- 1 sample RIR n°41 in the Danish population (of Austrian descent)
- 1 sample in the Slovakian population
- 2 samples RIR n°3 , n°49 in the German population (1 from Bavaria, 1 from Hagen)
- 1 sample RIR n°2 in the Swiss population (Bern)
- 2/1118 among 1118 RH:1,2,–3,4,5 donors, tested with a monoclonal anti-D (LOR17-6C7) and confirmed by genotyping in the German population (Baden-Wurttemberg) (Table 2)
- 2/500 among 500 D positive donors (inferred to comprise 187 RH:1,2,–3,4,5 samples), tested with a monoclonal anti-D (HIRO-7) and confirmed by genotyping in the Swiss population (Ticino, Italian-speaking Switzerland) (Table 2)
- 4/693 among 693 R1r blood donors, tested with a monoclonal anti-D (HIRO-7) and confirmed by genotyping in the Swiss population (Bern, German-speaking Switzerland) (Table 2)
- 0/1010 among 1010 RH:1,–2,3,4,5 donors, tested with a monoclonal anti-D (LOR17-6C7) and confirmed by genotyping in the German population (Baden-Wurttemberg) (Table 2)
- 0/768 among 768 RH:1,2,–3,4,5 donors, tested with a monoclonal anti-D (LOR17-6C7) and confirmed by genotyping in the Danish population (Aarhus) (Table 2)
- 2/250 250 donors with RH:1,2,–3,4,5 phenotype among 1000 donors screened for RHD molecular variants by several PCR-SSP and exon 5 sequencing of all samples (500 R0r, 250 R1R, 250 R2r) in the German population (southwestern Germany)
- 1/25 donors with "weak D or questionnable D status" explored by NGS to compare with Sanger sequencing in the Austrian population, Upper Austria
- 2/26 among 26 French Canadian with weak D phenotype or D positive phenotype and anti-D Caucasian, French Canadian
- 1/360 donors with atypical D phenotype (discrepancies or reactivity weaker than 3+) Brazilian
- 1/351 out of 351 prenatal patients with discrepant D phenotyping results (population tested 608486 patients) Canada
- 1 sample anti-D in a D positive individual Serbia
- 1/85 donors with weak D phenotype Bosnia Herzegovina
- 2/163 selected variants included for the development of a genotyping assay mainly in the Dutch population (samples may have been included in other studies)
- 2/430 (1 heterozygous) among samples with ambigous D phenotype in the French population (Table S1)
- 1/353 samples referred for discrepant or weak D typing in the USA population
- 1 hemizygote among 278 samples selected for the development of nonspecific quantitative next-generation sequencing. (non-random samples, may have been reported in other studies)
Allele or phenotype frequency
- 1/1295 estimated haplotype frequency among donors in the German population (Baden-Wurttemberg) (Table 2)
- 1/173 estimated phenotype frequency among RH:1,2,–3,4,5 donors in the Swiss population (Bern, German-speaking Switzerland) (Table 2)
- 1/389 estimated haplotype frequency among donors in the Swiss population (Bern, German-speaking Switzerland) (Table 2)
- 1/1644 estimated phenotype frequency among donors (all RHCE phenotypes) in the German population (Baden-Wurttemberg) (Table 2)
- 1/220 estimated haplotype frequency among donors in the Swiss population (Ticino, Italian-speaking Switzerland) (Table 2)
- <1/256 (upper limit of the 95% confidence interval) estimated phenotype frequency among RH:1,2,–3,4,5 donors in the Danish population (Aarhus) (Table 2)
- <1/605 (upper limit of the 95% confidence interval) estimated haplotype frequency among donors in the Swiss population (Bern, German-speaking Switzerland) (Table 2)
- 1/351 (CI: 1/105 - 1/1979) estimated population frequency among 1000 donors screened for RHD molecular variants by several PCR-SSP and exon 5 sequencing of all samples (500 R0r, 250 R1R, 250 R2r) in the German population (southwestern Germany)
- 1/559 estimated phenotype frequency among RH:1,2,–3,4,5 donors in the German population (Baden-Wurttemberg) (Table 2)
- <1/798 (upper limit of the 95% confidence interval) estimated phenotype frequency among donors (all RHCE phenotypes) in the Swiss population (Bern, German-speaking Switzerland) (Table 2)
- 1/538 estimated phenotype frequency among donors (all RHCE phenotypes) in the Swiss population (Bern, German-speaking Switzerland) (Table 2)
- 1/292 estimated phenotype frequency among donors (all RHCE phenotypes) in the Swiss population (Ticino, Italian-speaking Switzerland) (Table 2)
Structure mapping
Movement | Mouse Input | Touch Input | ||
---|---|---|---|---|
Rotation | Primary Mouse Button | Single touch | ||
Translation | Middle Mouse Button or Ctrl+Primary | Triple touch | ||
Zoom | Scroll Wheel or Second Mouse Button or Shift+Primary | Pinch (double touch) | ||
Slab | Ctrl+Second | Not Available |
References
- Avent ND et al. The rhesus blood group system: insights from recent advances in molecular biology. Transfus Med Rev, 1999. [Citation] [RHeference]
- Wagner FF et al. DNB: a partial D with anti-D frequent in Central Europe. Blood, 2002. [Citation] [RHeference]
- Noizat-Pirenne F et al. Serological studies of monoclonal RH antibodies with RH1 (D), RH2 (C), RH3 (E) and RH5 (e) variant RBCs. Transfus Clin Biol, 2003. [Citation] [RHeference]
- Chen Q et al. Random survey for RHD alleles among D+ European persons. Transfusion, 2005. [Citation] [RHeference]
- St-Louis M et al. Weak D type 42 cases found in individuals of European descent. Immunohematology, 2011. [Citation] [RHeference]
- Stabentheiner S et al. Overcoming methodical limits of standard RHD genotyping by next-generation sequencing. Vox Sang, 2011. [Citation] [RHeference]
- Daniels G et al. Variants of RhD--current testing and clinical consequences. Br J Haematol, 2013. [Citation] [RHeference]
- von Zabern I et al. D category IV: a group of clinically relevant and phylogenetically diverse partial D. Transfusion, 2013. [Citation] [RHeference]
- Fichou Y et al. Establishment of a medium-throughput approach for the genotyping of RHD variants and report of nine novel rare alleles. Transfusion, 2013. [Citation] [RHeference]
- Haer-Wigman L et al. RHD and RHCE variant and zygosity genotyping via multiplex ligation-dependent probe amplification. Transfusion, 2013. [Citation] [RHeference]
- Arnoni CP et al. How do we identify RHD variants using a practical molecular approach? Transfusion, 2014. [Citation] [RHeference]
- Wagner FF et al. The Rhesus Site. Transfus Med Hemother, 2014. [Citation] [RHeference]
- Lukacevic Krstic J et al. Anti-D Antibodies in Pregnant D Variant Antigen Carriers Initially Typed as RhD. Transfus Med Hemother, 2016. [Citation] [RHeference]
- Clarke G et al. Resolving variable maternal D typing using serology and genotyping in selected prenatal patients. Transfusion, 2016. [Citation] [RHeference]
- Quantock KM et al. Anti-D in a mother, hemizygous for the variant RHD*DNB gene, associated with hemolytic disease of the fetus and newborn. Transfusion, 2017. [Citation] [RHeference]
- S Vege et al. RHD Genotyping of Discrepant or Weak D Samples: Over a Year’s Experience. Transfusion, 2017. — Abstract — [RHeference]
- Guzijan G et al. Implementation of Molecular RHD Typing at Two Blood Transfusion Institutes from Southeastern Europe. Transfus Med Hemother, 2019. [Citation] [RHeference]
- Stef M et al. RH genotyping by nonspecific quantitative next-generation sequencing. Transfusion, 2020. [Citation] [RHeference]
- Floch A et al. Comment from Rheference Online ressource, 2020. — Online ressource — [RHeference]
- Vege S et al. Impact of RHD genotyping on transfusion practice in Denmark and the United States and identification of novel RHD alleles. Transfusion, 2021. [Citation] [RHeference]
Last update: Jan. 8, 2021